CSIMarket


Bicycle Therapeutics Plc  (BCYC)
Other Ticker:  
 


 

Bicycle Therapeutics Plc

BCYC's Financial Statements and Analysis



Bicycle Therapeutics Plc increased forth quarter of 2023 net loss per share of $-0.94 compare to net loss per share of $-0.87 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.26 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.94 $  5 Mill
$-0.07     $+2M     +67.38 %



Bicycle Therapeutics Plc's Revenue rose by 67.38 % in forth quarter of 2023 (Dec 31 2023) year on year, to $5 million and declined by -0.39 % sequentially.


Bicycle Therapeutics Plc is

More on BCYC's Income Statement



Bicycle Therapeutics Plc's in theforth quarter of 2023 recorded net loss of $-49.099 million, an increase from net loss of $-29.978 million in IV. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-49.898 million realized in previous quarter.

More on BCYC's Growth

Bicycle Therapeutics Plc Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-46 million, capital expenditures grew by -1.448-96.48%, to $0 millions compare to same quarter a year ago

More on BCYC's Cash flow Statement


Bicycle Therapeutics Plc does not pay out common stock dividend.

In trailing twelve-month period Bicycle Therapeutics Plc payed $ -1.70 cash per share, on a free-cash flow basis .

Book value fell by -0.78 % sequentially to $10.43 per share, -1.67% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 10.43 per share from $ 10.51.

Company repurchased 4.01 million shares or 10.14 % in Dec 31 2023.


More on BCYC's Dividends

 Market Capitalization (Millions) 872
 Shares Outstanding (Millions) 36
 Total Debt (Millions $) 31
 Revenue (TTM) (Millions $) 27
 Net Income (TTM) (Millions $) -181
 Cash Flow (TTM) (Millions $) 188
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Bicycle Therapeutics Plc does not pay out common stock dividend.

In trailing twelve-month period Bicycle Therapeutics Plc had negative $ -1.70 cash flow per share, on a free-cash flow basis .

Book value fell by -0.78 % sequentially to $10.43 per share, -1.67% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 10.43 per share from $ 10.51.

Company repurchased 4.01 million shares or 10.14 % in Dec 31 2023.


More on BCYC's Balance Sheets

 Market Capitalization (Millions) 872
 Shares Outstanding (Millions) 36
 Total Debt (Millions $) 31
 Revenue (TTM) (Millions $) 27
 Net Income (TTM) (Millions $) -181
 Cash Flow (TTM) (Millions $) 188
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Bicycle Therapeutics Plc Earnings

Bicycle Therapeutics Pedals to Success with 67% Revenue Growth in Q4 2023

The financial results for Bicycle Therapeutics Plc for the fourth quarter of 2023 paint an interesting picture of the company's performance. While the net shortfall widened to $-49.099 million compared to $-29.978 million in the prior year, there was a significant improvement in revenue, which grew by 67.378% to $5.33 million from $3.19 million in the comparable quarter a year ago.
It is worth noting that in a time when many companies in the Major Pharmaceutical Preparations industry are experiencing revenue declines, Bicycle Therapeutics Plc has managed to buck the trend and post a strong top-line improvement. This indicates that the company is making strides in its market and attracting attention despi...

Bicycle Therapeutics Plc Achieves Impressive 76.053% Revenue Growth in Q3 2023, Defying Market Challenges

Bicycle Therapeutics Plc, a biote...

1. Pharma Giant, Major Pharmaceutical Preparations, Struggles to Profit Despite Massive Revenue Surge in Fiscal 2023!

BCYC, a prominent player in the biotech industry, has recently announced a remarkable surge in revenue for the second quarter of the 2023 earnings season. The company reported a staggering rise of 160.324% year on year, reaching a record high of $11.40 million. Although the per-share shortfall increased to $-1.41, compared to the preceding reporting season, where it was $-1.30, the substantial revenue growth cannot be overlooked.
In the previous reporting season, BCYC experienced a doubled revenue of 132.782% from $4.90 million, showcasing the company's consistent growth and performance. Despite the increased shortfall per share, it is evident that BCYC has been successful in generating revenue and expan...

Bicycle Therapeutics Plc Powers Through Pandemic Impact with Impressive 26.839% Surge in Q1 2023 Revenue

Bicycle Therapeutics Plc, more com...


Date modified: 2024-02-20T15:54:49+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com